Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of malignant melanoma~* Metastatic Stage IV disease, or Stage III disease that is not surgically resectable~* ECOG Performance status of 0,1,or 2~* Adequate venous access~* Agreement to practice effective methods of birth control~* Hepatically impaired consistent with Child-Pugh classification Grade B~Exclusion Criteria:~* Chronic intravascular coagulopathy confirmed by the presence of fibrinogen degradation products, metastases to the liver, or exudative ascites~* Prior organ allograft~* Requirement for concomitant anticoagulant therapy (with the exception of 1 mg/day of warfarin for central line prophylaxis) while receiving protocol therapy~* Known hypersensitive to DTIC~* Prior treatment with Genasense

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).